Outcome of pregnancies in women receiving velaglucerase alfa for gaucher disease

Journal of Obstetrics and Gynaecology Research

Volumn 40, Issue 4, 2014, Pages 968-975

  Elstein, Deborah ^a   Hughes, Derralynn ^d   Goker Alpan, Ozlem ^e   Stivel, Miriam ^f   Baris, Hagit N ^b,c   Cohen, Ian J ^b,c   Granovsky Grisaru, Sorina ^a   Samueloff, Arnon ^a   Mehta, Atul ^d   Zimran, Ari ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^b RABIN MEDICAL CENTER   (Israel)

^c TEL AVIV UNIVERSITY   (Israel)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e O and O Alpan   (United States)

^f Hospital Privado del Colegio Médico de San Juan Ciudad de San Juan   (Argentina)

Author keywords

Enzyme replacement therapy; Gaucher disease; Neonatal outcome; Pregnancy; Velaglucerase alfa

Indexed keywords

HEMOGLOBIN; IMIGLUCERASE; VELAGLUCERASE ALFA; GLUCOSYLCERAMIDASE; RECOMBINANT PROTEIN; VELAGLUCERASE ALFA, HUMAN;

ABORTION; ADULT; ANEMIA; APGAR SCORE; ARTICLE; BIRTH WEIGHT; CESAREAN SECTION; CLINICAL ARTICLE; CONCEPTION; ENZYME REPLACEMENT; FEMALE; GAUCHER DISEASE; HIP ARTHROPLASTY; HUMAN; LIVE BIRTH; MISSED ABORTION; PARITY; POSTPARTUM HEMORRHAGE; PREGNANCY; PREGNANCY OUTCOME; REPRODUCTIVE TOXICITY; THROMBOCYTE COUNT; THROMBOCYTOPENIA; VAGINAL DELIVERY; ADVERSE EFFECTS; CLINICAL TRIAL; COHORT ANALYSIS; FOLLOW UP; GENETICS; MEDICAL RECORD; METABOLISM; MULTICENTER STUDY; PREGNANCY COMPLICATIONS;

COHORT STUDIES; ENZYME REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MEDICAL RECORDS; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME; RECOMBINANT PROTEINS;

EID: 84903593370     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/jog.12254     Document Type: Article

References (27)

1. Zimran A, Elstein D. Lipid storage diseases. In: Lichtman MA, Kipps T, Seligsohn U, Kaushansky K, Prchal JT (eds). Williams Hematology, 8th edn. New York: McGraw-Hill, 2010; 1065-1071.
2. Barton NW, Brady RO, Dambrosia JM et al. Replacement therapy for inherited enzyme deficiency-macrophagetargeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324: 1464-1470.
3. Elstein D, Granovsky-Grisaru S, Rabinowitz R, Kanai R, Abrahamov A, Zimran A. Use of enzyme replacement therapy for Gaucher disease during pregnancy. Am J Obstet Gynecol 1997; 177: 1509-1512.
4. Aporta Rodriguez R, Escobar Vedia JL, Navarro Castro AM, Aguilar García G, Cabrera Torres A. Alglucerase enzyme replacement therapy used safely and effectively throughout the whole pregnancy of a Gaucher disease patient. Haematologica 1998; 83: 852-853.
5. Cleary JE, Burke WM, Baxi LV. Pregnancy after avascular necrosis of the femur complicating Gaucher's disease. Am J Obstet Gynecol 2001; 184: 233-234.
6. Sherer Y, Dulitzki M, Levy Y, Livneh A, Shoenfeld Y, Langevitz P. Successful pregnancy outcome in a patient with Gaucher's disease and antiphospholipid syndrome. Ann Hematol 2002; 81: 161-163.
7. Torloni MR, Franco K, Sass N. Gaucher's disease with myocardial involvement in pregnancy. Sao Paulo Med J 2002; 120: 90-92.
8. Elstein Y, Eisenberg V, Granovsky-Grisaru S et al. Pregnancies in Gaucher disease: A five-year study. Am J Obstet Gynecol 2004; 190: 435-441.
9. Granovsky-Grisaru S, Aboulafia Y, Diamant YZ, Horowitz M, Abrahamov A, Zimran A. Gynecologic and obstetric aspects of Gaucher's disease: A survey of 53 patients. Am J Obstet Gynecol 1995; 172 (4 Pt 1): 1284-1290.
10. Gillis S, Hyam E, Abrahamov A, Elstein D, Zimran A. Platelet function abnormalities in Gaucher disease patients. Am J Hematol 1999; 61: 103-106.
11. Simchen MJ, Oz R, Shenkman B, Zimran A, Elstein D, Kenet G. Impaired platelet function and peripartum bleeding in women with Gaucher disease. Thromb Haemost 2011; 105: 509-514.
12. Cox TM, Aerts JM, Belmatoug N et al. Management of nonneuronopathic Gaucher disease with special reference to pregnancy, splenectomy, bisphosphonate therapy, use of biomarkers and bone disease monitoring. J Inherit Metab Dis 2008; 31: 319-336.
13. Zimran A, Morris E, Mengel E et al. The female Gaucher patient: The impact of enzyme replacement therapy around key reproductive events (menstruation, pregnancy and menopause). Blood Cells Mol Dis 2009; 43: 264-288.
14. Granovsky-Grisaru S, Belmatoug N, vom Dahl S, Mengel E, Morris E, Zimran A. The management of pregnancy in Gaucher disease. Eur J Obstet Gynecol Reprod Biol 2011; 156: 3-8.
15. Zimran A, Altarescu G, Phillips M et al. Phase I/II and extension study of velaglucerase alfa (Gene-ActivatedTM human glucocerebrosidase) replacement therapy in adults with type 1 Gaucher disease: 48-month experience. Blood 2010; 115: 4651-4656.
16. Hollak CE, vom Dahl S, Aerts JM et al. Force Majeure: Therapeutic measures in response to restricted supply of imiglucerase (Cerezyme) for patients with Gaucher disease. Blood Cells Mol Dis 2010; 44: 41-47.
17. Cox TM. Recommendations for treating patients with Gaucher disease with emerging enzyme products. Blood Cells Mol Dis 2010; 44: 84-85.
18. Ioscovich A, Elstein Y, Halpern S, Vatashsky E, Grisaru-Granovsky S, Elstein D. Anesthesia for obstetric patients with Gaucher disease: Survey and review. Int J Obstet Anesth 2004; 13: 244-250.
19. FDA: Food and Drug Administration Center for Evaluation and Research Pregnancy Labeling Subcommittee of the Advisory Committee for Reproductive Health Drugs. [Cited 26 Mar 2001.] Available from URL: http://www.fda.gov/ohrms/ dockets/ac/00/transcripts/3601tl.rtf
20. Guideline on the exposure to medicinal products: Need for post-authorisation data (EMEA/CHMP/313666/2005).
21. VPRIV®, package insert, Shire HGT, Lexington, MA.
22. Burrow TA, Grabowski GA. Velaglucerase alfa in the treatment of Gaucher disease type 1. Clin Investig (Lond) 2011; 1: 285-293.
23. Pernoll ML, Garmel SH. Early pregnancy risks. In: DeCherney AH, Nathan L, Goodwin TM, Laufer N (eds). Current Obstetric & Gynecologic Diagnosis & Treatment, 10th edn. New York: Mc-Graw-Hill, 2003; 306-330.
24. Elstein D, Altarescu G, Maayan H et al. Booster-effect with velaglucerase alfa in patients with Gaucher disease switched from long-term imiglucerase therapy: Early Access Program results from Jerusalem. Blood Cells Mol Dis 2012; 48: 45-50.
25. Sekijima Y, Ohashi T, Ohira S, Kosho T, Fukushima Y. Successful pregnancy and lactation outcome in a patient with Gaucher disease receiving enzyme replacement therapy, and the subsequent distribution and excretion of imiglucerase in human breast milk. Clin Ther 2010; 32: 2048-2052.
26. Merkatz RB. Inclusion of women in clinical trials:A historical overview of scientific, ethical, and legal issues. J Obstet Gynecol Neonatal Nurs 1998; 27: 78-84.
27. Allesee L, Gallagher CM. Pregnancy and protection: The ethics of limiting a pregnant woman's participation in clinical trials. J Clin Res Bioeth 2011; 2 (108). pii: 1000108.